Contribute Try STAT+ Today

Cytokinetics and Amgen on Friday presented a deeper analysis from a large clinical trial of their chronic heart failure drug, showing a greater benefit for subgroups of patients with more advanced heart failure.

The new findings are somewhat better than the initial study results presented in October. However, the drug, omecamtiv mecarbil, still does not help heart failure patients live longer, so questions about its future — and Amgen’s commitment to it — remain unanswered.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.